Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer
Authors:
- Lisanne MoutLMLisanne Mout
- Stefan A.J. BuckSBStefan A.J. Buck
- Pim J. FrenchPFPim J. French
- Ron H.J. MathijssenRMRon H.J. Mathijssen
Open Access
- 5 November 2021
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 73, 103681
Abstract
No abstract availableKeywords
Funding Information
- Sanofi (PC346C-DCC-K)
- Sanofi (GSE185587)
This publication has 32 references indexed in Scilit:
- Trimmomatic: a flexible trimmer for Illumina sequence dataBioinformatics, 2014
- featureCounts: an efficient general purpose program for assigning sequence reads to genomic featuresBioinformatics, 2013
- STAR: ultrafast universal RNA-seq alignerBioinformatics, 2012
- Quality control and preprocessing of metagenomic datasetsBioinformatics, 2011
- Rapid functional dissection of genetic networks via tissue-specific transduction and RNAi in mouse embryosNature Medicine, 2010
- Truncated ETV1, Fused to Novel Tissue-Specific Genes, and Full-Length ETV1 in Prostate CancerCancer Research, 2008
- Cancer Cells Display Profound Intra- and Interline Variation following Prolonged Exposure to Antimitotic DrugsCancer Cell, 2008
- The Human PC346 Xenograft and Cell Line Panel: A Model System for Prostate Cancer ProgressionEuropean Urology, 2006
- Androgen receptor modifications in prostate cancer cells upon long‐termandrogen ablation and antiandrogen treatmentInternational Journal of Cancer, 2005
- In vivo amplification of the androgen receptor gene and progression of human prostate cancerNature Genetics, 1995